On July 27, 2022 AKSO Biopharmaceutical, Inc. ("AKSO"), a global biopharmaceutical company with an innovative and comprehensive approach to treat cancer, autoimmune disease, and genetic disorder, reported the publication in the Journal of Experimental Medicine of preclinical data demonstrating that AKSO’s late preclinical stage molecule AB001 effectively inhibits growth of Multiple Myeloma ("MM") and Diffuse Large B Cell Lymphoma ("DLBCL") in mice (Press release, AKSO Biopharmaceutical, JUL 27, 2022, View Source [SID1234617024]). Importantly, AB001 was also found to be nontoxic in non-human primates.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"AB001 is a first-in-class and potentially best-in-class ligand trap targeting APRIL and BAFF, which are known to be difficult to sequester due to high native binding affinities to their receptors, but also critical regulators of B cell development and survival," said Professor Amato Giaccia, AKSO’s Chairman and Senior Scientific Strategist. "Our study demonstrated the novel mechanism of APRIL and BAFF in modulating protein translation; and suggest that engineered soluble BCMA could be a superior alternative to therapeutics either approved or in development for MM and DLBCL."
"Safe and effective targeted therapies are urgently needed for MM and DLBCL patients who exhaust currently available treatment options," said Dr. Rebecca Miao, AKSO’s Chief Scientific Officer. "Collectively, our data support AB001 as a clinically viable candidate for the treatment of MM and DLBCL. Furthermore, the biological functions of BAFF and APRIL are not limited to B cell malignancies but extend to autoimmune disorders and other diseases triggered by pathological B cells, indicating a broad clinical application of AB001."
Key findings from the study performed under the guidance of Professor Giaccia and Dr. Miao, reported in the publication titled "Developing High-Affinity Decoy Receptor Optimized for Multiple Myeloma and Diffuse Large B Cell Lymphoma Treatment", include:
APRIL and BAFF mediated signalling is required for MM progression;
When compared to the wild-type soluble BCMA receptor, AB001 shows 500-fold stronger binding toward BAFF and 4-fold stronger binding toward APRIL;
AB001 is capable of neutralizing APRIL and BAFF and their receptor activities, impacting protein translation and production in MM and DLBCL cells;
Treatment with AB001 led to enhanced antitumor activity in a number of MM and DLBCL mouse models;
AB001 also demonstrated an adequate toxicity profile and on-target mechanism of action in nonhuman primate studies.
ABOUT AB001
AB001 is a late preclinical stage first-in-class and best-in-class engineered soluble BCMA decoy receptor. AB001 traps APRIL and BAFF with ultra-high binding affinities thereby inhibiting ligand mediated activation of receptors BCMA, BAFF Receptor and TACI.